Pregene Enters into Innovative Partnership with CellPoint to Develop Anti-BCMA CAR-T Cell Therapy in Europe and the US

By
Justin.choi
-
0
24
Shenzhen Pregene Biopharma and CellPoint announced an exclusive license agreement for the development and commercialization of PRG-1801, Pregene’s single domain antibody-based anti-BCMA chimeric antigen receptor (CAR) T cell program, for the treatment of hematological indications in Europe and the United States.
[Shenzhen Pregene Biopharma Co. Ltd (Cision US, Inc.)]

Sorry, but the selected Zotpress account can't be found.

Press Release